Epidermal growth factor receptor mutations in non-small cell lung cancers in a multiethnic Malaysian patient population

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 1, 2014, Pages 321-326

  Liam, Chong Kin ^a   Leow, Hwong Ruey ^a   How, Soon Hin ^b   Pang, Yong Kek ^a   Chua, Keong Tiong ^a   Lim, Boon Khaw ^a   Lai, Nai Lang ^a   Kuan, Yeh Chunn ^b   Pailoor, Jayalakshmi ^a   Rajadurai, Pathmanathan ^c,d  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA   (Malaysia)

^c Sime Darby Medical Centre   (Malaysia)

^d MONASH UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

EGFR mutation; Malaysian; Multiethnic; Non small cell lung cancer; Smoking

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; ASIAN; ETHNOLOGY; EXON; FEMALE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALAYSIA; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; PROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALAYSIA; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEX FACTORS; SMOKING;

EID: 84894064176     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.1.321     Document Type: Article

References (46)

1. Arrieta O, Cardona AF, Federico Bramuglia G, et al (2011). Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol, 6, 1955-9.
2. Baik CS, Pritchard CC, Eaton KD, Chow LQ (2013). EGFR mutations in squamous cell lung cancer in never-smokers. J Thorac Oncol, 8, 6-7.
3. Cortes-Funes H, Gomez C, Rosell R, et al (2005). Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small cell lung cancer patients. Ann Oncol, 16, 1081-6.
4. Department of Statistics, Malaysia. Population Distribution and Basic Demographic Characteristics: Population and Housing Census of Malaysia 2010.
5. Ebbert JO, Yang P, Vachon CM, et al (2003) Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J Clin Oncol, 21, 921-6.
6. EGFR RGQ PCR Kit Handbook for qualitative measurement of 29 somatic mutations in the EGFR oncogene.06/2011. QIAGEN Manchester Ltd, Skelton House, Lloyd Street.
7. Han S-W, Kim T-Y, Hwang PG, et al (2005). Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol, 23, 2493-501.
8. Herbst RS, Heymach JV, Lippman SM (2008). Lung cancer. N Engl J Med, 359, 1367-80.
9. Huang SF, Liu HP, Li LH, et al (2004). High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res, 10, 8195-203.
10. Huang YS, Yang JJ, Zhang XC, et al (2011). Impact of smoking status and pathologic type on epidermal growth factor receptor mutations in lung cancer. Chin Med J, 124, 2457-60.
11. Jemal A, Siegel R, Ward E, et al (2006). Cancer statistics, 2006. CA Cancer J Clin, 56, 106-30.
12. Kimura H, Fujiwara Y, Sone T, et al (2006). High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci, 97, 642-8.
13. Kosaka T, Yatabe Y, Endoh H, et al (2004). Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res, 64, 8919-23.
14. Li C, Fang R, Sun Y, et al (2011). Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One, 6, 28204.
15. Liam CK, Pang YK, Leow CH, Shyamala P, Menon AA (2006). Changes in the distribution of lung cancer cell types and patient demography in a developing multiracial Asian country. Lung Cancer, 53, 23-30.
16. Liang Z, Zhang J, Zeng X, et al (2010). Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer, 10, 376.
17. Lindeman NI, Cagle PT, Beasley MB, et al (2013). Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol, 8, 823-59.
18. Lund-Iversen M, Kleinberg L, Fjellbirkeland L, Helland A, Brustugun OT (2012). Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. J Thorac Oncol, 7, 1471-3.
19. Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39.
20. Maheswaran S, Sequist LV, Nagrath S, et al (2008). Detection of mutations in EGFR in circulating lung-cancer cells. Engl J Med, 359, 366-77.
21. Mitsudomi T, Kosaka T, Endoh H, et al (2005). Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol, 23, 2513-20.
22. Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57.
23. Oken MM, Creech RH, Tormey DC, et al (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5, 649-55.
24. Paez JG, Jänne PA, Lee JC, et al (2004). EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science, 304, 1497-500.
25. Paik PK, Varghese AM, Sima CS, et al (2012). Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. Mol Cancer Ther, 11, 2535-40.
26. Pallis AG, Voutsina A, Kalikaki A, et al (2007). 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer, 11, 1560-6.
27. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
28. Perez-Moreno P, Brambilla E, Thomas R, Soria JC (2012). Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res, 18, 2443-51.
29. th Edition of TNM in Lung Cancer: What Now? J Thorac Oncol, 4, 671-673.
30. QIAamp ® DNA FFPE Tissue Handbook for purification of genomic DNA from formalin-fixed, paraffin-embedded tissues 10/2007.
31. st ed. Philadelphia: WB Saunders Co, 45-72.
32. Rosell R, Moran T, Queralt C, et al (2009). Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 361, 958-67.
33. Sahoo R, Harini VV, Babu VC, et al (2011). Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer, 73, 316-9.
34. Salto-Tellez M, Tsao MS, Shih JY, et al (2011). Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer. A Combined Clinical-Molecular Pathological Approach. J Thorac Oncol, 6, 1663-9.
35. Sequist LV, Heist RS, Shaw AT, et al (2011). Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol, 22, 2616-24.
36. Sharma SV, Bell DW, Settleman J, Haber DA (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 7, 169-81.
37. Shigematsu H, Lin L, Takahashi T, et al (2005). Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 97, 339-46.
38. Sonobe M, Manabe T, Wada H, Tanaka F (2005). Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer, 93, 355-63.
39. Sun YH, Fang R, Gao B, et al (2010). Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. Acta Pharmacol Sin, 31, 647-8.
40. Sun PL, Seol H, Lee HJ, et al (2012). High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol, 7, 323-30.
41. Takano T, Ohe Y, Sakamoto H, et al (2005). Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small cell lung cancer. J Clin Oncol, 23, 6829-37.
42. Taron M, Ichinose Y, Rosell R, et al (2005). Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res, 11, 5878-85.
43. Third Report of the National Cancer Registry, Cancer incidence in Malaysia, 2003-2005, National Cancer Registry, Malaysia (http://www.crc.gov.my/ncr).
44. Vital statistics Malaysia (2005). Department of Statistics, Malaysia 2006.
45. Wagenknecht LE, Cutter GR, Haley NJ, et al (1990). Racial differences in serum cotinine levels among smokers in the coronary artery risk development in (young) adults study. Am J Public Health, 80, 1053-6.
46. Wang J, Ramakrishnan R, Tang Z, et al (2010). Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays. Clin Chem, 56, 623-32.